Antibodies

23 Mar 2009 Xencor Licenses Xtend Antibody Half-Life Prolongation Platform to Merck & Co., Inc.
19 Mar 2009 Neoprobe’s Phase 3 Lymphoseek Study Achieves Positive Results
18 Mar 2009 InflaRx Closes Funding to Move Its Complement Antibody Program into Clinical Trials for Sepsis Treatment
18 Mar 2009 Herceptin now shown to significantly prolong the lives of patients with HER2-positive advanced stomach cancer
18 Mar 2009 Provenance Biopharmaceuticals Corp. Announces License Agreement with Merck Serono for the Development and Commercialization of Novel Immunocytokine for the Treatment of Cancer
17 Mar 2009 Emergent BioSolutions Announces Commencement of Phase I/II Clinical Trial of Anthrax Immune Globulin for Treating Anthrax Disease
16 Mar 2009 YM BIOSCIENCES ANNOUNCES FIRST PATIENT ENROLLED IN MULTI-NATIONAL, RANDOMIZED, DOUBLE-BLIND TRIAL OF NIMOTUZUMAB IN NON-SMALL-CELL LUNG CANCER
12 Mar 2009 Phase III Study of Rituxan in Lupus Nephritis Did Not Meet Primary Endpoint
12 Mar 2009 Micromet, Inc. To Regain Rights to Blinatumomab in North America; Reports Financial Results for the Fourth Quarter and Full Year ended December 31, 2008
12 Mar 2009 Biothera Receives Approval to Launch Two Phase II Lung Cancer Trials
10 Mar 2009 Tolerx Expands Phase 3 ‘DEFEND’ Trial of Otelixizumab in Europe
09 Mar 2009 Arana successfully completes Phase II psoriasis study
06 Mar 2009 Symphogen and Origen Collaborate to Produce Transgenic Chicken for Generation of Fully Human Antibody Therapeutics
04 Mar 2009 XOMA Initiates Phase 2a Clinical Trial With XOMA 052 in Patients With Rheumatoid Arthritis
03 Mar 2009 FDA Provides A Positive Review of InNexus Biotechnology Development Plan for Lead Product
02 Mar 2009 Morphotek(R), Inc. Announces Initiation of MORAb-009 Phase II Study in First- Line Treatment of Mesothelioma
02 Mar 2009 ImmunoGen, Inc. Earns Milestone Payment with Genentech's Start of Trastuzumab-DM1 (T-DM1) Phase III Clinical Testing; Other T-DM1 Progress Reported
02 Mar 2009 ImClone Systems and Bristol-Myers Squibb Update Status of First-Line Squamous Cell Carcinoma of the Head and Neck Supplemental Biologics Application for ERBITUX(R) in U.S.
02 Mar 2009 Xencor and Pfizer Enter into Antibody Technology Licensing Agreement
27 Feb 2009 MabThera approved in the EU for patients with chronic lymphocytic leukaemia
27 Feb 2009 BioInvent Presents Positive Preclinical Data for BI-505 in Myeloma
27 Feb 2009 Crucell's Revolutionary Antibody for Universal Therapy Against Flu
26 Feb 2009 Arzerra(TM) (ofatumumab) MAA Accepted by EMEA
25 Feb 2009 Seattle Genetics Completes Enrollment in Lintuzumab Phase IIb Clinical Trial for Patients with Acute
25 Feb 2009 Implicit Licenses Clinical Stage Antibody Program From Lilly

La Merie Biologics

FREE Weekly News Bulletin

Sign Up

2017 Sales ofAntibodies & Proteins

New Product Alert

For La Merie Publishing

Sign Up
Top